There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Intec Pharma Ltd (NASDAQ: NTEC) and Dermira (NASDAQ: DERM) with bullish sentiments.
Intec Pharma Ltd (NASDAQ: NTEC)
Oppenheimer analyst Jay Olson maintained a Buy rating on Intec Pharma Ltd (NASDAQ: NTEC) today and set a price target of $15. The company’s shares opened today at $4.58, close to its 52-week low of $4.38.
“We met with NTEC CEO the company’s 1Q update and came away more optimistic about the execution of Accordion Pill (AP) plans on several fronts. We are encouraged by the progress being made on the clinical program and preparation for commercial scale manufacturing. With >350 patients enrolled out of an expected ~420 for the Ph3 ACCORDANCE study, we believe NTEC is well positioned to complete enrollment in 4Q18, as previously guided. Separately, NTEC has partnered with a global leader in formulation and film technology for commercial scale production of FDA-compliant facility. With $43M in cash, NTEC is funded until 2020, well past Ph3 data. We update our model and reiterate our Outperform rating with $15 PT.”
According to TipRanks.com, Olson is a 1-star analyst with an average return of -1.4% and a 44.3% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Eiger Biopharmaceuticals, and Conatus Pharmaceuticals.
Currently, the analyst consensus on Intec Pharma Ltd is Strong Buy and the average price target is $14.33, representing a 213.2% upside.
In a report issued on May 15, Maxim Group also maintained a Buy rating on the stock with a $12 price target.
Dermira (NASDAQ: DERM)
Cantor Fitzgerald analyst Louise Chen assigned a Buy rating to Dermira (NASDAQ: DERM) today and set a price target of $20. The company’s shares opened today at $8.11, close to its 52-week low of $6.98.
“: DERM’s management team and guest speakers, Amy S. Paller, Northwestern University, hosted an Analyst & Investor Day today to underscore the opportunities for: glycopyrronium tosylate (excessive sweating) and Lebrikizumab (atopic dermatitis). DERM’s stock was down 23% (S&P flat) post the event, but we see no fundamental reason for the weakness. In short, investors we spoke with were concerned that consensus numbers need to come down.”
According to TipRanks.com, Chen ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -8.0% and a 39.1% success rate. Chen covers the Healthcare sector, focusing on stocks such as Aclaris Therapeutics Inc, Paratek Pharmaceuticals, and Spero Therapeutics Inc.
Dermira has an analyst consensus of Moderate Buy, with a price target consensus of $18.25.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.